323 related articles for article (PubMed ID: 34663326)
21. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.
Romero-Brufau S; Chopra A; Ryu AJ; Gel E; Raskar R; Kremers W; Anderson KS; Subramanian J; Krishnamurthy B; Singh A; Pasupathy K; Dong Y; O'Horo JC; Wilson WR; Mitchell O; Kingsley TC
BMJ; 2021 May; 373():n1087. PubMed ID: 33980718
[TBL] [Abstract][Full Text] [Related]
22. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
National Immunization Advisory Committee Technical Working Group
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1035-1059. PubMed ID: 33131228
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
Dagan N; Barda N; Biron-Shental T; Makov-Assif M; Key C; Kohane IS; Hernán MA; Lipsitch M; Hernandez-Diaz S; Reis BY; Balicer RD
Nat Med; 2021 Oct; 27(10):1693-1695. PubMed ID: 34493859
[TBL] [Abstract][Full Text] [Related]
24. Healthcare Staff Perceptions Following Inoculation with the BNT162b2 mRNA COVID-19 Vaccine at University Hospitals Coventry & Warwickshire NHS Trust.
Robbins T; Kyrou I; Clark C; Sharma K; Laird S; Berry L; Morgan N; Patel K; Sankar S; Randeva H
Int J Environ Res Public Health; 2021 Sep; 18(17):. PubMed ID: 34501970
[No Abstract] [Full Text] [Related]
25. Impact of COVID-19 vaccination on COVID-19 hospital admissions in England during 2021: an observational study.
Cornforth F; Webber L; Kerr G; Dinsdale H; Majeed A; Greengross P
J R Soc Med; 2023 May; 116(5):167-176. PubMed ID: 36825557
[TBL] [Abstract][Full Text] [Related]
26. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model.
Paranthaman K; Subbarao S; Andrews N; Kirsebom F; Gower C; Lopez-Bernal J; Ramsay M; Copas A
Age Ageing; 2022 May; 51(5):. PubMed ID: 35596946
[TBL] [Abstract][Full Text] [Related]
28. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
29. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.
Imai N; Rawson T; Knock ES; Sonabend R; Elmaci Y; Perez-Guzman PN; Whittles LK; Kanapram DT; Gaythorpe KAM; Hinsley W; Djaafara BA; Wang H; Fraser K; FitzJohn RG; Hogan AB; Doohan P; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet Public Health; 2023 Mar; 8(3):e174-e183. PubMed ID: 36774945
[TBL] [Abstract][Full Text] [Related]
30. Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.
Halder A; Imamura H; Condon S; Boroughs K; Nilsson SC; Anderson T; Caterson ID
Intern Med J; 2022 Jan; 52(1):121-124. PubMed ID: 35060290
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
Salmerón Ríos S; Mas Romero M; Cortés Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Señalada JJB; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Murillo Romero A; Lauschke VM; Stebbing J; Abizanda P
J Am Geriatr Soc; 2021 Jun; 69(6):1441-1447. PubMed ID: 33768521
[TBL] [Abstract][Full Text] [Related]
33. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
35. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.
McMurry R; Lenehan P; Awasthi S; Silvert E; Puranik A; Pawlowski C; Venkatakrishnan AJ; Anand P; Agarwal V; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Carlson K; Doddahonnaiah D; Metzger A; Kayal N; Berner G; Ramudu E; Carpenter C; Wagner T; Rajasekharan A; Soundararajan V
Med; 2021 Aug; 2(8):965-978.e5. PubMed ID: 34230920
[TBL] [Abstract][Full Text] [Related]
36. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
37. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study.
Cabezas C; Coma E; Mora-Fernandez N; Li X; Martinez-Marcos M; Fina F; Fabregas M; Hermosilla E; Jover A; Contel JC; Lejardi Y; Enfedaque B; Argimon JM; Medina-Peralta M; Prieto-Alhambra D
BMJ; 2021 Aug; 374():n1868. PubMed ID: 34407952
[TBL] [Abstract][Full Text] [Related]
38. [Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers].
Rojkovich B; Németh D; Török E; Szabó B; Pintér Á; Juhász I; Weidl M; Lányi É; Pável-Szecskó J; Lázár I; Perduk A; Reiter J; Nagy G; Nagy E; Géher P
Orv Hetil; 2021 Sep; 162(39):1551-1557. PubMed ID: 34570721
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
Itzhaki Ben Zadok O; Shaul AA; Ben-Avraham B; Yaari V; Ben Zvi H; Shostak Y; Pertzov B; Eliakim-Raz N; Abed G; Abuhazira M; Barac YD; Mats I; Kramer MR; Aravot D; Kornowski R; Ben-Gal T
Eur J Heart Fail; 2021 Sep; 23(9):1555-1559. PubMed ID: 33963635
[TBL] [Abstract][Full Text] [Related]
40. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines.
Botton J; Dray-Spira R; Baricault B; Drouin J; Bertrand M; Jabagi MJ; Weill A; Zureik M
Vaccine; 2022 Jan; 40(3):414-417. PubMed ID: 34924220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
